| Acute coronary syndrome (ACS)is an important form of coronary heart disease,including a series of myocardial ischemic event,unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI) and ST-segment elevation myocardial infarction (STEMI). Clinical research identified,mainly inflammatory cell-mediated plaque rupture, and thrombosis,as as a key factor in ACS pathophysiology. Activation of inflammation and inbalance of immune regulation lead to the insibility of Atherosclerotic plaque.ACS patients with immune dysfunction has been confirmed by many studies. T lymphocytes , important immune cells ,participate in both cellular immunity and humoral immunity . CD3+ T-lymphocytes was divided into CD4 + and CD8 + subsets. CD4 + subsets, the helper / induced T Cells, indcue the pre-mature cytotoxic T lymphocytes into mature cytotoxic T lymphocytes,and enhance the B lymphocytes cells to produce antibodies and the activation of macrophage. CD8 + T cells, the inhibition / killer T Cells, play a role in the negative regulation of immune response by itself and Inhiitor.it can suppress the funtion of CD4 + T cells and B lymphocytes,thus restrain other functions,such as the fomation of antibodies and immune response. Generally,CD4 + T cells and CD8 + T cells are under balance.Once the balance broken,there will be disorders in the immune system,which will lead to a serial of pathological changes, Promote the occurrence and development of atherosclerosis. It suggests the intervention of immunity could be a method to treate the ACS.wenyangyiqi tang can enhance immune function, antioxidant,improve endothelial function, and suppress the degradation of extracellular matrix in fibrous plaque, then stablized the Vulnerable Plaque. But there are few reports about But there are few reports about the treatment of ACS with wenyangyiqi tang.ObjectiveTo observe the level of T-lymphocyte subpopulation in blood of patients with acute coronary syndrome, and to probe the effects of Wenyangyiqi on T-lymphocyte subpopulations and its prognosis in patients with acute coronary syndrome.Data and methodsEighty 106 acute coronary syndrome patients(ACS group) and 40 non- acute coronary syndrome(NC group) treated in our hospital from February,2008 to February,2010,assayed its level of T-lymphocyte subpopulation in blood by SAP method.The ACS group were radomized into two groups: treated group (n=55) and control group(n=51).Two groups were treated with Conventional treatment and Wenyangyiqi tang added to the treated group, its levels of T-lymphocyte subpopulation in blood were detected before discharged.The level of CD8+ was higher than that in group NC(P<0.01),but the level of CD3+,CD4+ and CD4+/ CD8+ in group ACS was less than that in group NC(P<0.01) . Compared with the control group , the level of CD8+ was decreased and the level of CD3+,CD4+ and CD4+/ CD8+ was gradual increased in the treated group before discharged,there was significant difference between the treated and control group (P<0.05) .However,the average length of stay in the treanted group reduced (P>0.05).In 1-months follow-up, there was some dicreased in the incidence of cardiovascular adverse events in the treated group,but, there is no significant difference between the two groups(P>0.05).ConclusionsThe cellular immune in ACS patients is unbalance,and it may play an important role in the forming and progress of ACS.Wenyangyiqi tang can remarkably correct the imbalanced cellular immune system and does Shorten the average length of stay and decrease the incidence of cardiovascular adverse events.It suggests the intervention of immunity could be a method to treate the ACS.
|
PDF Full Text Request